Seth Sullivan
Family Medicine · Norwalk, CTNPI 1750496048
Payments from drug & device makers
Across 70 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$291
- AstraZeneca$276
- Novo Nordisk$171
- Merck$91
- Myriad Women's Health, Inc.$90
- Amgen$83
- plus $561 from 16 others
What the payments were for
- Food & beverage$1,563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 12 | $291 |
| AstraZeneca(2 entities) | 14 | $276 |
| Novo Nordisk | 7 | $171 |
| Merck | 4 | $91 |
| Myriad Women's Health, Inc. | 1 | $90 |
| Amgen | 4 | $83 |
| Kaleo, Inc. | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Bayer | 2 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| AbbVie | 2 | $48 |
| Lilly USA, LLC | 2 | $43 |
| Neos Therapeutics, LP | 2 | $41 |
| Tris Pharma Inc | 2 | $34 |
| Corcept Therapeutics | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Boehringer Ingelheim | 1 | $20 |
| Intra-sana Laboratories | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
How this compares
$1,563 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $83,746 |
| CreonLipase/Protease/Amylase | 18 | $38,701 |
| JardianceEmpagliflozin | 21 | $28,948 |
| XareltoRivaroxaban | 16 | $20,698 |
| FarxigaDapagliflozin Propanediol | 30 | $20,449 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $8,233 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,584 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,976 |
| Lagevrio (Eua)Molnupiravir | 12 | $4,731 |
| Rosuvastatin Calcium | 94 | $2,273 |
| Ezetimibe | 39 | $1,856 |
| Celecoxib | 27 | $1,782 |
| Metoprolol Succinate | 95 | $1,586 |
| Atorvastatin Calcium | 160 | $1,375 |
| Tamsulosin Hcl | 52 | $1,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $83,74683 claims |
| AbbVieCreon, Synthroid | $48 | $39,84643 claims |
| Boehringer IngelheimJardiance | $20 | $28,94821 claims |
| AstraZenecaFarxiga | $276 | $20,44930 claims |
| MerckJanumet, Lagevrio (Eua) | $91 | $12,96428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Norwalk
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
- Helar CamposNew London$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.